MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517042914 A) filed by Garuda Therapeutics, Inc., Cambridge, U.S.A., on May 2, for 'erythroid lineages derived from pluripotent cells.'
Inventor(s) include Shah, Dhvanit.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure, in various aspects and embodiments, provides methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), and megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells. In various embodiments, the invention provides for efficient ex vivo processes for developing such hematopoietic lineages, including but not limited to progenitor erythroblast cells and erythroblast cell lineages, from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or bone marrow. The present invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy."
The patent application was internationally filed on Oct. 05, 2023, under International application No.PCT/US2023/076093.
Disclaimer: Curated by HT Syndication.
